Diem Nguyen Net Worth

Diem Nguyen biography

Dr. Diem Nguyen serves as Director of the Company. Dr. Nguyen most recently served as Executive Vice President, Biopharma, at PPD, Inc., a leading global clinical research organization providing integrated drug development, laboratory, and lifecycle management services. Prior to joining PPD, she held various commercial leadership and general management roles at Pfizer, including Global President, Americas, Pfizer Essential Health, and Global Sterile Injectables. She also served as Pfizer's Regional President, North America, Global Established Pharma; General Manager, Global Biosimilars; and Vice President, Established Products Strategy. Prior to Pfizer, Dr. Nguyen led corporate development, including all company-wide mergers and acquisitions and investor relations at Serologicals Corporation. She received a B.A. in Chemistry from the University of Virginia, a Ph.D. in Biochemistry and Molecular Genetics from the University of Virginia, and an M.B.A. from the Darden Graduate School of Business Administration at the University of Virginia. Dr. Nguyen also currently serves as a trustee at the Children's Hospital of Philadelphia.

How old is Diem Nguyen?

Diem Nguyen is 48, he's been the Director of Verrica Pharmaceuticals Inc since 2020. There are 11 older and 2 younger executives at Verrica Pharmaceuticals Inc. The oldest executive at Verrica Pharmaceuticals Inc is Lawrence Eichenfield, 62, who is the Director.

What's Diem Nguyen's mailing address?

Diem's mailing address filed with the SEC is C/O VERRICA PHARMACEUTICALS INC., 44 WEST GAY STREET, SUITE 400, WEST CHESTER, PA, 19380.

Insiders trading at Verrica Pharmaceuticals Inc

Over the last 6 years, insiders at Verrica Pharmaceuticals Inc have traded over $8,200,904 worth of Verrica Pharmaceuticals Inc stock and bought 11,305,854 units worth $62,586,502 . The most active insiders traders include Advisors Llcperceptive Life..., Paul B Manning a John A Iii Stalfort. On average, Verrica Pharmaceuticals Inc executives and independent directors trade stock every 20 days with the average trade being worth of $213,456. The most recent stock trade was executed by Christopher G. Hayes on 26 August 2024, trading 35,713 units of VRCA stock currently worth $93,211.

What does Verrica Pharmaceuticals Inc do?

verrica pharmaceuticals inc., a clinical stage medical dermatology company, develops and commercializes dermatological treatments in the united states. the company's lead product candidate include vp-102 that is in phase iii clinical trial for the treatment of molluscum contagiosum; in phase ii clinical trial for the treatment of common warts; and completed phase i clinical trial for the treatment of genital warts. it is also developing cantharidin-based product candidate, vp-103 for the treatment of plantar warts. the company has a license agreement with lytix biopharma as to develop and commercialize ltx-315 for dermatologic oncology indications. verrica pharmaceuticals inc. was founded in 2013 and is headquartered in west chester, pennsylvania.

Verrica Pharmaceuticals Inc executives and stock owners

Verrica Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Ted White,
  President, Chief Executive Officer, Director
• Brian Davis,
  Chief Financial Officer
• Joe Bonaccorso,
  Chief Commercial Officer
• Ted White,
  Pres, CEO & Director
• Dr. Gary Goldenberg M.D.,
  Chief Medical Officer
• Mark Prygocki,
  Independent Director
• Gary Goldenberg,
  Chief Medical Officer
• Craig Ballaron,
  Independent Director
• Sean Stalfort,
  Director
• Diem Nguyen,
  Director
• Lawrence Eichenfield,
  Director
• Bradley Catalone,
  Head of Drug Development
• Patrick Burnett,
  Chief Medical Officer
• Christopher Hayes,
  General Counsel, Corporate Secretary, Chief Legal Officer
• Paul Manning,
  Chairman of the Board
• Dr. Bradley J. Catalone MBA, Ph.D.,
  Head of Drug Devel.
• Eugene Scavola,
  Exec. VP of Technical Operations
• Joe Bonaccorso,
  Chief Commercial Officer
• Christopher G. Hayes,
  Chief Legal Officer, Sec. & Gen. Counsel
• P. Terence Kohler,
  Chief Financial Officer
• Matt Davidson,
  10% owner
• John A Iii Stalfort,
  Director
• Glenn A Oclassen,
  Director
• Advisors Llcperceptive Life...,
  
• Linda Palczuk,
  Chief Operating Officer
• Chris Degnan,
  Chief Financial Officer
• Terry Kohler,
  CHIEF FINANCIAL OFFICER